A68S (p.Ala68Ser) variant of FBN2 (Fibrillin-2)

A68S (p.Ala68Ser) in FBN2 (Fibrillin-2) is a missense change. Clinical records from EBI and UniProt describe it as likely benign. The available variant effect predictions contribute to a CATVariant prioritization score of 0.16 / 1. The record also includes population frequency data, published literature, and structural context.

A68S (p.Ala68Ser) variant details